Point Therapeutics reports talabostat's mechanism may open new approach for treating cancer

New York, April 26 - Point Therapeutics, Inc. disclosed new preclinical data further explaining talabostat's dual mechanism of action - and said its double means of working opens a potential new approach for treating cancer.

Talabostat is a targeted agent that inhibits dipeptidyl peptidases, enzymes that regulate biological processes, including tumor growth and immune responses.

As a stromal targeted agent, talabostat inhibits fibroblast activation protein, a dipeptidyl peptidases that has been shown to contribute to tumor growth.

In the latest findings, Point also announced that talabostat targets DPP 8 and DPP 9, which have been demonstrated to enhance immune functions in preclinical studies.

"These proof of concept data are important because they validate a preclinical mechanism that is quite unique in oncology," said Charles Dinarello, professor of medicine at the University of Colorado School of Medicine and a member of Point Therapeutics' scientific advisory board, in a news release.

"The very nature of talabostat's dual mechanism of action speaks to its potential versatility as a targeted agent with broad utility in several different cancers."

Point is a Boston-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.